timolol has been researched along with carvedilol in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 10 (47.62) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Gaillard, P; Schambel, P; Testa, B | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Baker, JG | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Bard, B; Carrupt, PA; Martel, S | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chang, Q; Chen, Z; Hu, G; Hu, L; Li, Q; Long, J | 1 |
| Abuin, L; Cotecchia, S; Lattion, A; Nenniger-Tosato, M | 1 |
| Harada, K; Kohmoto, O; Komuro, I; Maruyama, T; Matsui, H; Matsuo, H; Nagai, R; Oyama, T; Serizawa, T; Shimizu, T; Sugishita, Y; Takahashi, T; Yao, A | 1 |
| Fonarow, GC | 1 |
| Borer, JS; Camm, AJ; Danchin, N; Ferrari, R; Fox, K; Lopez Sendon, JL; Steg, PG; Tardif, JC; Tavazzi, L; Tendera, M | 1 |
| Pisklak, DM; Wawer, I; Zielińska-Pisklak, MA | 1 |
| Baumann-Durchschein, F; Bucsics, T; Datz, C; Dolak, W; Ferlitsch, A; Fickert, P; Finkenstedt, A; Graziadei, I; Hametner, S; Karnel, F; Krones, E; Maieron, A; Mandorfer, M; Peck-Radosavljevic, M; Püspök, A; Rainer, F; Reiberger, T; Schoder, M; Schöfl, R; Schwabl, P; Stadlbauer, V; Stauber, R; Tilg, H; Trauner, M; Zoller, H | 1 |
| Aigner, A; Horn, K; Kirsten, H; Loeffler, M; Nenoff, K; Pott, J; Regenthal, R; Rode, M; Scholz, M; Teren, A; Thiery, J; Wirkner, K | 1 |
3 review(s) available for timolol and carvedilol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Beta-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations.
Topics: Adrenergic beta-Antagonists; Algorithms; Atenolol; Carbazoles; Carvedilol; Humans; Myocardial Infarction; Practice Guidelines as Topic; Propanolamines; Propranolol; Randomized Controlled Trials as Topic; Secondary Prevention; Timolol | 2006 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Cardiac Output, Low; Cardiovascular Diseases; Carvedilol; Coronary Artery Disease; Coronary Disease; Exercise Test; Heart Rate; Humans; Metoprolol; Multivariate Analysis; Myocardial Infarction; Myocardial Ischemia; Prognosis; Propanolamines; Risk Assessment; Risk Factors; Timolol; Ventricular Dysfunction, Left | 2007 |
18 other study(ies) available for timolol and carvedilol
| Article | Year |
|---|---|
Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.
Topics: Indoles; Ligands; Models, Molecular; Molecular Conformation; Molecular Structure; Piperazines; Propanolamines; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin; Structure-Activity Relationship; Tetrahydronaphthalenes | 1996 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Algorithms; Animals; Cell Line; CHO Cells; Cricetinae; Dioxoles; Humans; Propanolamines; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Receptors, Adrenergic, beta-3 | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
Topics: Chemistry, Pharmaceutical; Chromatography; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Pharmaceutical Preparations; Solubility; Technology, Pharmaceutical | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Repositioning; Drug Screening Assays, Antitumor; Humans; Melanoma; Molecular Docking Simulation; Molecular Structure; Propanols; Skin Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Constitutively active mutants of the beta1-adrenergic receptor.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Amino Acid Substitution; Betaxolol; Carbazoles; Carvedilol; Cell Line; Cyclic AMP; Epinephrine; Humans; Imidazoles; Isoproterenol; Labetalol; Point Mutation; Practolol; Propanolamines; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Recombinant Proteins; Timolol | 1999 |
Characteristic effects of alpha1-beta1,2-adrenergic blocking agent, carvedilol, on [Ca2+]i in ventricular myocytes compared with those of timolol and atenolol.
Topics: Adrenergic Antagonists; Adrenergic beta-Antagonists; Animals; Atenolol; Calcium; Calcium Channels, L-Type; Carbazoles; Carvedilol; Guinea Pigs; Heart Ventricles; In Vitro Techniques; Intracellular Membranes; Male; Myocytes, Cardiac; Osmolar Concentration; Propanolamines; Receptors, Adrenergic, beta; Timolol | 2003 |
1H and 13C NMR characteristics of β-blockers.
Topics: Acebutolol; Acids; Adrenergic beta-Antagonists; Alkalies; Alprenolol; Atenolol; Carbazoles; Carbon Isotopes; Carvedilol; Nuclear Magnetic Resonance, Biomolecular; Pindolol; Propanolamines; Propranolol; Protons; Timolol | 2011 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Liver Cirrhosis; Mass Screening; Propanolamines; Propranolol; Randomized Controlled Trials as Topic; Timolol | 2017 |
Impact of medication on blood transcriptome reveals off-target regulations of beta-blockers.
Topics: Adrenergic beta-Antagonists; Adult; Carvedilol; Humans; Hypertension; Leukocytes, Mononuclear; Timolol; Transcriptome | 2022 |